US FDA and EPA to set nanoparticle regulations

11 December 2006

The US Environmental Protection Agency has decided to regulate the use of nanoparticles based on silver in consumer goods. The precious metal is considered to have antibacterial properties. Although the ingestion by humans of large quantities of silver produces tissue-impregnation with silver sulphate and can lead to argyria, a blue or grey-blue skin coloration, the oral consumption of silver is not generally considered toxic.

The development of silver nanoparticles which claim to have antibacterial properties is causing both the EPA and the Food and Drug Administration to reconsider their respective regulatory frameworks. Environmental campaigning organizations claim that discharges of the particles, for example from laundry machines, could harm human-beneficial bacteria and wildlife.

According to www.mineweb.com, a mining industry on-line magazine, "scientists believe that the very nature of nanotechnology - its ability to alter the fundamental properties of substances - is likely to challenge the existing regulatory structure and generate confusion concerning the role of the regulation."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight